Our findings not only underscore the promise of SEC14L3 as a therapeutic target but also unveil an SEC14L3/RPS3/NFκB positive feedback loop that curtails ccRCC progression. The gene discussed is SEC14L3; the disease is nonpapillary renal cell carcinoma.